OBJECTIVE: Dysrhythmias, hemodynamic instability, congestive heart failure, and sudden death are serious complications of human immunodeficiency virus (HIV) infection that, to our knowledge, have not been studied systematically. We sought to determine the cumulative incidence and clinical predictors of these adverse events in a cohort of HIV-infected children. DESIGN: Historical cohort study. SETTING: University-affiliated, primary and tertiary care pediatric hospital and ambulatory care center. PARTICIPANTS: Eighty-one HIV-infected children who had one or more cardiac evaluations between 1984 and 1991 form the study cohort. The initial cardiac evaluation occurred at a median age of 1.5 years, and children were followed up to a median age of 3.6 years. MAIN OUTCOME MEASURES: Mortality (related to cardiac dysfunction as well as noncardiac causes), tachycardia, bradycardia, hypertension, hypotension, marked sinus arrhythmia, cardiac arrest, and chronic congestive heart failure. RESULTS: Hemodynamic abnormalities and dysrhythmias occurred frequently. Eight unexpected cardiorespiratory arrests occurred in seven children (9%). Chronic congestive heart failure was noted in 10% of patients. Thirty children died, 10 with significant cardiac dysfunction. As HIV-infected children progressed from acquired immunodeficiency syndrome (AIDS)-related complex to AIDS, significant cardiac problems were more likely to occur. Both nonneurologic AIDS and encephalopathy were strongly associated with most severe cardiac outcomes. However, encephalopathy was the strongest correlate of cardiorespiratory arrest (P = .002). Epstein-Barr virus coinfection was the strongest correlate of chronic congestive heart failure (P < .001). CONCLUSIONS: Cardiac morbidity and mortality are more common with advanced HIV infection. The presence of encephalopathy or Epstein-Barr virus coinfection identifies HIV-infected children at especially high risk for adverse cardiac outcomes.
OBJECTIVE:Dysrhythmias, hemodynamic instability, congestive heart failure, and sudden death are serious complications of human immunodeficiency virus (HIV) infection that, to our knowledge, have not been studied systematically. We sought to determine the cumulative incidence and clinical predictors of these adverse events in a cohort of HIV-infectedchildren. DESIGN: Historical cohort study. SETTING: University-affiliated, primary and tertiary care pediatric hospital and ambulatory care center. PARTICIPANTS: Eighty-one HIV-infectedchildren who had one or more cardiac evaluations between 1984 and 1991 form the study cohort. The initial cardiac evaluation occurred at a median age of 1.5 years, and children were followed up to a median age of 3.6 years. MAIN OUTCOME MEASURES: Mortality (related to cardiac dysfunction as well as noncardiac causes), tachycardia, bradycardia, hypertension, hypotension, marked sinus arrhythmia, cardiac arrest, and chronic congestive heart failure. RESULTS:Hemodynamic abnormalities and dysrhythmias occurred frequently. Eight unexpected cardiorespiratory arrests occurred in seven children (9%). Chronic congestive heart failure was noted in 10% of patients. Thirty children died, 10 with significant cardiac dysfunction. As HIV-infectedchildren progressed from acquired immunodeficiency syndrome (AIDS)-related complex to AIDS, significant cardiac problems were more likely to occur. Both nonneurologic AIDS and encephalopathy were strongly associated with most severe cardiac outcomes. However, encephalopathy was the strongest correlate of cardiorespiratory arrest (P = .002). Epstein-Barr virus coinfection was the strongest correlate of chronic congestive heart failure (P < .001). CONCLUSIONS: Cardiac morbidity and mortality are more common with advanced HIV infection. The presence of encephalopathy or Epstein-Barr virus coinfection identifies HIV-infectedchildren at especially high risk for adverse cardiac outcomes.
Authors: Steven E Lipshultz; William T Shearer; Bruce Thompson; Kenneth C Rich; Irene Cheng; E John Orav; Sulekha Kumar; Ricardo H Pignatelli; Louis I Bezold; Philip LaRussa; Thomas J Starc; Julie S Glickstein; Sharon O'Brien; Ellen R Cooper; James D Wilkinson; Tracie L Miller; Steven D Colan Journal: J Am Coll Cardiol Date: 2011-01-04 Impact factor: 24.094
Authors: C Langston; E R Cooper; J Goldfarb; K A Easley; S Husak; S Sunkle; T J Starc; A A Colin Journal: Pediatrics Date: 2001-02 Impact factor: 7.124
Authors: Amy E Sims Sanyahumbi; Mina C Hosseinipour; Danielle Guffey; Irving Hoffman; Peter N Kazembe; Madeline McCrary; Charles G Minard; Charles van der Horst; Craig A Sable Journal: Pediatr Infect Dis J Date: 2017-07 Impact factor: 2.129
Authors: Steven E Lipshultz; Kirk A Easley; E John Orav; Samuel Kaplan; Thomas J Starc; J Timothy Bricker; Wyman W Lai; Douglas S Moodie; George Sopko; Mark D Schluchter; Steven D Colan Journal: Lancet Date: 2002-08-03 Impact factor: 79.321
Authors: W W Lai; S E Lipshultz; K A Easley; T J Starc; S E Drant; J T Bricker; S D Colan; D S Moodie; G Sopko; S Kaplan Journal: J Am Coll Cardiol Date: 1998-11-15 Impact factor: 24.094